Dr. Heather Wakelee, Stanford University Medical Center, discusses the purpose of adjuvant chemotherapy, and which patients benefit most from it.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.
Modifying Factors: Should Patients with Smaller Resected Node-Negative NSCLC Tumors Receive Adjuvant Chemo?
While post-operative chemotherapy for early stage NSCLC is a well-established standard for relatively healthy patients with stage II or higher resected cancers, the question of whether adjuvant chemotherapy is more likely to help or hurt a patient remains more a matter of debate.
Challenging Cases Podcast: Experts Weigh in on Adjuvant Chemo Option for Smaller Node-Negative NSCLC with Some Higher Risk Features
Continuing with this series of case-based podcasts we've done in partnership with LUNGevity, we'll again have a series of experts offer their own perspective to another challenging scenario. All are with the same format of me hosting and presenting the case to Drs. Bob Doebele from University of Colorado and Jyoti Patel from Northwestern University, who participated in the live webinar version of this, then followed in the recording by other terrific colleagues of mine weighing on the same case. These experts are: